Adjuvant Radiation Therapy for Thoracic Soft Tissue Sarcomas: A Population-Based Analysis

ConclusionsThis population-based analysis is the largest dataset of primary thoracic STSs to date and suggests significant survival benefit associated with adjuvant RT. The improvement in OS was more notable in patients with high-grade tumors. Randomized prospective studies are warranted to further understand the benefit of RT in this group.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

Using a national cancer registry, we demonstrate that insurance status is associated with differences in stage of diagnosis, receipt of neoadjuvant or adjuvant radiation therapy, and overall survival for patients with soft tissue sarcoma in the United States. These insurance related disparities are most prominent in Medicaid and uninsured patients
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionsThis population-based analysis is the largest dataset of primary thoracic STS to date and suggests significant survival benefit associated with adjuvant RT. The improvement in overall survival was more notable in patients with high-grade tumors. Randomized prospective studies are warranted to further understand the benefit of RT in this group.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
CONCLUSIONS: This population-based analysis is the largest dataset of primary thoracic STS to date and suggests significant survival benefit associated with adjuvant RT. The improvement in overall survival was more notable in patients with high-grade tumors. Randomized prospective studies are warranted to further understand the benefit of RT in this group. PMID: 31520633 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
Using a national cancer registry, we demonstrate that insurance status is associated with differences in stage of diagnosis, receipt of neoadjuvant or adjuvant radiation therapy, and overall survival for patients with soft tissue sarcoma in the United States. These insurance related disparities are most prominent in Medicaid and uninsured patients
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
AbstractFibrous dysplasia (FD) is generally considered to be a benign disease that affects the bones, but it has potential to become malignant over time, generally several decades after its initial diagnosis. Radiation therapy can induce malignant transformation of FD; however, reports have indicated a few cases of malignant transformation of FD in the absence of radiation therapy. Angiosarcoma is a particularly rare type of cancer in the oral region, which accounts for less than 1% of all soft-tissue sarcomas. Herein, we reported a case of a 62-year-old man with monostotic FD of the left maxilla of over 50  years&rsq...
Source: Oral Radiology - Category: Radiology Source Type: research
We describe the incidental detection of a radiation-induced undifferentiated soft-tissue sarcoma with increased uptake on Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in a prostate cancer patient previously treated with surgery and external-beam radiotherapy. Results were confirmed by histological analysis. Ga-PSMA is known to bind not only to PSMA-expressing prostate cancer cells but also to the neovasculature of various other solid tumors. A careful Ga-PSMA PET/CT review of previously irradiated areas is warranted so as not to miss radiation-induced sarcoma in prostate cancer patients. PMID: 31274636 ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Nucl Med Source Type: research
We describe the incidental detection of a radiation-induced undifferentiated soft-tissue sarcoma with increased uptake on 68Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in a prostate cancer patient previously treated with surgery and external-beam radiotherapy. Results were confirmed by histological analysis. 68Ga-PSMA is known to bind not only to PSMA-expressing prostate cancer cells but also to the neovasculature of various other solid tumors. A careful 68Ga-PSMA PET/CT review of previously irradiated areas is warranted so as not to miss radiation-induced sarcoma in prostate cancer patients.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Authors: Saiz AM, Gingrich AA, Canter RJ, Kirane AR, Monjazeb AM, Randall RL, Thorpe SW Abstract Radiation therapy (RT) is advocated in the multimodal treatment of high-grade soft tissue sarcoma (STS), but its role may be less clear in chemotherapy-sensitive STS such as extraskeletal Ewing sarcoma (EES). The purpose of this study was to determine the role of RT on overall survival (OS) in localized EES adult patients treated with chemotherapy and surgery. Adult patients diagnosed with EES and reported to the National Cancer Database from 2004 to 2014 were evaluated. All patients were treated with surgical resection...
Source: Sarcoma - Category: Cancer & Oncology Tags: Sarcoma Source Type: research
Up to 60% of patients (pts) with prostate cancer that extends beyond the prostatic capsule will have positive resection margins following radical prostatectomy. Post-operative radiation therapy (PostOp) is routinely offered to those pts. Although this improves local control and overall survival, it results in significantly more late toxicity than surgery alone. Pre-operative radiation therapy (PreOp) has become the standard for soft tissue sarcoma and rectal cancer, improving local control and reducing toxicity compared to PostOp.
Source: Journal of Medical Imaging and Radiation Sciences - Category: Radiology Authors: Source Type: research
By BISHAL GYAWALI, MD Keynote speech on the JAVELIN not going far enough to improve survival The treatment landscape for metastatic renal-cell carcinoma has changed dramatically with the introduction of immunotherapies. Unfortunately though, we are promoting combinations over single agents without having much idea of added benefit of each drug. This is an important issue because when we combine two drugs, the only thing we are certain of are the added toxicities. PD-1 inhibitor nivolumab had improved OS when given in second line, however nivolumab was tested in combination with ipilimumab (not as a nivolumab monother...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Bishal Gyawali Clinical Trials Oncology PD-1 inhibitor Source Type: blogs
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Databases & Libraries | Radiation Therapy | Sarcomas | Soft Tissue Sarcoma | Study